365 related articles for article (PubMed ID: 11751105)
1. Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia.
Petraitiene R; Petraitis V; Groll AH; Sein T; Schaufele RL; Francesconi A; Bacher J; Avila NA; Walsh TJ
Antimicrob Agents Chemother; 2002 Jan; 46(1):12-23. PubMed ID: 11751105
[TBL] [Abstract][Full Text] [Related]
2. Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia.
Petraitiene R; Petraitis V; Groll AH; Sein T; Piscitelli S; Candelario M; Field-Ridley A; Avila N; Bacher J; Walsh TJ
Antimicrob Agents Chemother; 2001 Mar; 45(3):857-69. PubMed ID: 11181372
[TBL] [Abstract][Full Text] [Related]
3. Caspofungin: antifungal activity in vitro, pharmacokinetics, and effects on fungal load and animal survival in neutropenic rats with invasive pulmonary aspergillosis.
van Vianen W; de Marie S; ten Kate MT; Mathot RA; Bakker-Woudenberg IA
J Antimicrob Chemother; 2006 Apr; 57(4):732-40. PubMed ID: 16464895
[TBL] [Abstract][Full Text] [Related]
4. Antifungal efficacy, safety, and single-dose pharmacokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits.
Petraitis V; Petraitiene R; Groll AH; Bell A; Callender DP; Sein T; Schaufele RL; McMillian CL; Bacher J; Walsh TJ
Antimicrob Agents Chemother; 1998 Nov; 42(11):2898-905. PubMed ID: 9797223
[TBL] [Abstract][Full Text] [Related]
5. Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits.
Petraitis V; Petraitiene R; Groll AH; Roussillon K; Hemmings M; Lyman CA; Sein T; Bacher J; Bekersky I; Walsh TJ
Antimicrob Agents Chemother; 2002 Jun; 46(6):1857-69. PubMed ID: 12019101
[TBL] [Abstract][Full Text] [Related]
6. Efficacy, safety, and plasma pharmacokinetics of escalating dosages of intravenously administered ravuconazole lysine phosphoester for treatment of experimental pulmonary aspergillosis in persistently neutropenic rabbits.
Petraitiene R; Petraitis V; Lyman CA; Groll AH; Mickiene D; Peter J; Bacher J; Roussillon K; Hemmings M; Armstrong D; Avila NA; Walsh TJ
Antimicrob Agents Chemother; 2004 Apr; 48(4):1188-96. PubMed ID: 15047519
[TBL] [Abstract][Full Text] [Related]
7. Caspofungin prolongs survival of transiently neutropenic rats with advanced-stage invasive pulmonary aspergillosis.
van de Sande WW; van Vianen W; ten Kate MT; Vissers J; Laurijsens J; Tavakol M; Rijnders BJ; Mathot RA; Bakker-Woudenberg IA
Antimicrob Agents Chemother; 2008 Apr; 52(4):1345-50. PubMed ID: 18195059
[TBL] [Abstract][Full Text] [Related]
8. Combination Therapy with Isavuconazole and Micafungin for Treatment of Experimental Invasive Pulmonary Aspergillosis.
Petraitis V; Petraitiene R; McCarthy MW; Kovanda LL; Zaw MH; Hussain K; Shaikh N; Maung BBW; Sekhon NK; Hope WW; Walsh TJ
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28696236
[TBL] [Abstract][Full Text] [Related]
9. Assessing the antifungal activity, pharmacokinetics, and tissue distribution of amphotericin B following the administration of Abelcet and AmBisome in combination with caspofungin to rats infected with Aspergillus fumigatus.
Wasan KM; Sivak O; Rosland M; Risovic V; Bartlett K
J Pharm Sci; 2007 Jul; 96(7):1737-47. PubMed ID: 17080414
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling.
Groll AH; Mickiene D; Petraitiene R; Petraitis V; Lyman CA; Bacher JS; Piscitelli SC; Walsh TJ
Antimicrob Agents Chemother; 2001 Oct; 45(10):2845-55. PubMed ID: 11557479
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of the combination of voriconazole and caspofungin in experimental pulmonary aspergillosis by different Aspergillus species.
Zhang M; Su X; Sun WK; Chen F; Xu XY; Shi Y
Mycopathologia; 2014 Feb; 177(1-2):11-8. PubMed ID: 24306184
[TBL] [Abstract][Full Text] [Related]
12. Liposomal nystatin against experimental pulmonary aspergillosis in persistently neutropenic rabbits: efficacy, safety and non-compartmental pharmacokinetics.
Groll AH; Gonzalez CE; Giri N; Kligys K; Love W; Peter J; Feuerstein E; Bacher J; Piscitelli SC; Walsh TJ
J Antimicrob Chemother; 1999 Jan; 43(1):95-103. PubMed ID: 10381106
[TBL] [Abstract][Full Text] [Related]
13. Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin.
Petraitis V; Petraitiene R; Sarafandi AA; Kelaher AM; Lyman CA; Casler HE; Sein T; Groll AH; Bacher J; Avila NA; Walsh TJ
J Infect Dis; 2003 Jun; 187(12):1834-43. PubMed ID: 12792859
[TBL] [Abstract][Full Text] [Related]
14. Comparison of galactomannan detection, PCR-enzyme-linked immunosorbent assay, and real-time PCR for diagnosis of invasive aspergillosis in a neutropenic rat model and effect of caspofungin acetate.
Scotter JM; Chambers ST
Clin Diagn Lab Immunol; 2005 Nov; 12(11):1322-7. PubMed ID: 16275948
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of caspofungin alone and in combination with voriconazole in a Guinea pig model of invasive aspergillosis.
Kirkpatrick WR; Perea S; Coco BJ; Patterson TF
Antimicrob Agents Chemother; 2002 Aug; 46(8):2564-8. PubMed ID: 12121933
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of amphotericin B or amphotericin B-intralipid in combination with caspofungin against experimental aspergillosis.
Sionov E; Mendlovic S; Segal E
J Infect; 2006 Aug; 53(2):131-9. PubMed ID: 16360214
[TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity.
Wiederhold NP; Kontoyiannis DP; Chi J; Prince RA; Tam VH; Lewis RE
J Infect Dis; 2004 Oct; 190(8):1464-71. PubMed ID: 15378439
[TBL] [Abstract][Full Text] [Related]
18. Caspofungin: pharmacology, safety and therapeutic potential in superficial and invasive fungal infections.
Groll AH; Walsh TJ
Expert Opin Investig Drugs; 2001 Aug; 10(8):1545-58. PubMed ID: 11772269
[TBL] [Abstract][Full Text] [Related]
19. Pharmacodynamics of Posaconazole in Experimental Invasive Pulmonary Aspergillosis: Utility of Serum Galactomannan as a Dynamic Endpoint of Antifungal Efficacy.
Gastine S; Hope W; Hempel G; Petraitiene R; Petraitis V; Mickiene D; Bacher J; Walsh TJ; Groll AH
Antimicrob Agents Chemother; 2021 Jan; 65(2):. PubMed ID: 33168606
[No Abstract] [Full Text] [Related]
20. Evaluation of serum sandwich enzyme-linked immunosorbent assay for circulating galactomannan during caspofungin therapy: results from the caspofungin invasive aspergillosis study.
Maertens J; Glasmacher A; Selleslag D; Ngai A; Ryan D; Layton M; Taylor A; Sable C; Kartsonis N
Clin Infect Dis; 2005 Jul; 41(1):e9-14. PubMed ID: 15937754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
